Eli Lilly to invest USD 5.3bn in obesity drug production
US Novo Nordisk competitor Eli Lilly will spend USD 5.3bn on increasing production of a key ingredient in its weight loss and diabetes treatments after their explosive popularity led to shortages.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.